国药现代子公司法莫替丁注射液通过仿制药一致性评价

Core Viewpoint - The announcement by China National Pharmaceutical Group Modern (国药现代) regarding the approval of Famotidine injection by the National Medical Products Administration highlights a significant development in the company's product portfolio and its potential impact on the market for gastrointestinal medications [1]. Company Summary - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received the approval for Famotidine injection, which has passed the consistency evaluation of generic drug quality and efficacy [1]. - Famotidine is classified as a histamine H2 receptor antagonist, primarily used for treating upper gastrointestinal bleeding caused by peptic ulcers and other non-tumor-related conditions leading to gastric and duodenal mucosal erosion and bleeding [1].